ReviewAmerican journal of cancer research2015
TOX gene: a novel target for human cancer gene therapy.
Review in American journal of cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- Identification and Characterisation of Canine Osteosarcoma Biomarkers and Therapeutic Targets.Cancers · 2026Article
- Low expression of TOX predicts poor prognosis of patients with breast cancer in the real world: A retrospective study.Heliyon · 2025Article
- Transcriptomic and intervention evidence reveals domestic dogs as a promising model for anti-inflammatory investigation.Aging cell · 2024Article
- Single-cell ATAC sequencing identifies sleepy macrophages during reciprocity of cytokines inMicrobiology spectrum · 2024Article
- Exhausted T cells hijacking the cancer-immunity cycle: Assets and liabilities.Frontiers in immunology · 2023Review
- Novel immune subtypes identification of HER2-positive breast cancer based on immunogenomic landscape.Medical oncology (Northwood, London, England) · 2022Article
- The genomic and transcriptional landscape of primary central nervous system lymphoma.Nature communications · 2022Article
- CD4+ T cells in classical Hodgkin lymphoma express exhaustion associated transcription factors TOX and TOX2: Characterizing CD4+ T cells in Hodgkin lymphoma.Oncoimmunology · 2022Article
- Review
- Deciphering the Role of 3D Genome Organization in Breast Cancer Susceptibility.Frontiers in genetics · 2021Article
- Clinical characterization, genetic profiling, and immune infiltration of TOX in diffuse gliomas.Journal of translational medicine · 2020Article
- TOX: a rediscovered master molecular actor to enhance immuno-oncology interventions.Cellular & molecular immunology · 2020Article
- Potential Use of Biotherapeutic Bacteria to Target Colorectal Cancer-Associated Taxa.International journal of molecular sciences · 2020Review
- TOX3 is a favorable prognostic indicator and potential immunomodulatory factor in lung adenocarcinoma.Oncology letters · 2019Article
- PDCD5 regulates iNKT cell terminal maturation and iNKT1 fate decision.Cellular & molecular immunology · 2019Article
- Relationships between SNPs and prognosis of breast cancer and pathogenic mechanism.Molecular genetics & genomic medicine · 2019Article
- An Update on Molecular Biology of Cutaneous T Cell Lymphoma.Frontiers in oncology · 2019Review
- The Four Horsemen in Colon Cancer.Journal of oncology · 2019Review
- Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk.Proceedings of the National Academy of Sciences of the United States of America · 2018Article
- TOX and ADIPOQ Gene Polymorphisms Are Associated with Antipsychotic-Induced Weight Gain in Han Chinese.Scientific reports · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymocyte selection-associated high mobility group box factor (TOX) is a member of an evolutionarily conserved DNA-binding protein family and is expressed in several immune-relevant cell subsets. TOX encodes a nuclear protein of the high-mobility group box superfamily. It contains a DNA-binding domain, which allows it to regulate transcription by modifying local chromatin structure and modulating the formation of multi-protein complexes. Previous studies have shown that TOX play important roles in immune system. More recently, several studies have described TOX expression is frequently upregulated in diverse types of human tumors and the overregulation often associates with tumor progression. Moreover, TOXis involved in the control of cell apoptosis, growth, metastasis, DNA repair and so on. In this review, we provide an overview of current knowledge concerning the role of TOX in tumor development and progression biology function. To our knowledge, this is the first review about the role of thisnew oncogene in tumor development and progression.
Indexed as
Identifiers
26885442PMC4731627W2402501947What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.